Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Health leaders at the International AIDS Society (IAS) 2025 conference in Kigali have warned that shrinking funding and ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

There are over 100,000 HIV+ Texans. Trump's 'big beautiful' bill would slash funding for federal HIV prevention, medications, ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...